Covered recipient · General Payments record
CHARLES E LUBASH
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$891.58
- Reported across 45 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $315.00 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $43.05 | 2 |
| BeiGene USA, Inc. | $29.30 | 1 |
| Astellas Pharma US Inc | $27.75 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $27.25 | 1 |
| Acerta Pharma LLC | $26.27 | 1 |
| GlaxoSmithKline, LLC. | $23.06 | 1 |
| SOBI, INC | $22.94 | 1 |
| Amgen Inc. | $18.93 | 1 |
| Mirati Therapeutics, Inc. | $17.82 | 1 |
| Rigel Pharmaceuticals, Inc. | $16.21 | 1 |
| Daiichi Sankyo Inc. | $16.11 | 1 |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 1 |
| ABBVIE INC. | $15.76 | 1 |
| EMD Serono, Inc. | $14.61 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.76 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107562122 | CMS |
| Amgen Inc. | $18.93 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115884803 | CMS |
| Astellas Pharma US Inc | $27.75 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139506751 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.27 | 07/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105362174 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $27.25 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086302300 | CMS |
| BeiGene USA, Inc. | $29.30 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120853135 | CMS |
| Daiichi Sankyo Inc. | $16.11 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089450128 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101361920 | CMS |
| EMD Serono, Inc. | $14.61 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120262278 | CMS |
| GlaxoSmithKline, LLC. | $23.06 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116147893 | CMS |
| Mirati Therapeutics, Inc. | $17.82 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117166217 | CMS |
| PFIZER INC. | $20.73 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131721718 | CMS |
| PFIZER INC. | $22.32 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131390823 | CMS |
| Rigel Pharmaceuticals, Inc. | $16.21 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145203593 | CMS |
| SOBI, INC | $22.94 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141418836 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.